Ekso Bionics Holdings Inc

Ekso Bionics Holdings Inc(EKSO)の株式分析

$11.800

+0.009 (+0.08%)終値時点

Loading chart…
High
11.800
Open
11.650
VWAP
11.39
Vol
100.57K
Mkt Cap
19.08M
Low
10.560
Amount
1.15M
EV/EBITDA, TTM
-1.52

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

AI analysis of Ekso Bionics Holdings Inc (EKSO)

sell

EKSO is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock has short-term technical strength, but the business fundamentals are weak, there is no fresh news catalyst, no supportive options activity, and no strong institutional or insider buying signal. I would not buy this name now; the better call is to avoid it and wait for a materially stronger fundamental setup.

Analyst Ratings (1)

Buy
1 Buy
0 Hold
0 Sell
Current: 11.80
安値
平均
高値

H.C. Wainwright

2025-11-18

目標株価

$6

Buy

Lake Street

2025-07-29

目標株価

$15

Buy

HC Wainwright & Co.

2025-03-04

目標株価

$9

Strong Buy

Lake Street

2025-03-04

目標株価

$1

Strong Buy

HC Wainwright & Co.

2025-01-14

目標株価

$9

Strong Buy

バリュエーション指標

The current forward P/E ratio for Ekso Bionics Holdings Inc (EKSO) is 0.00, compared to its 5-year average forward P/E of -2.65.

Forward P/E

Strongly Overvalued
5Y Average P/E
-2.65
Current P/E
0.00
割高
-1.39
割安
-3.90

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-0.13
Current EV/EBITDA
-1.52
割高
0.32
割安
-0.58

Forward P/S

Fair
5Y Average P/S
1.30
Current P/S
1.70
割高
2.20
割安
0.39

Alphio AI Price Scenarios for EKSO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EKSO

$0.34

シナリオ価格

B

Base

Base · 50%EKSO

$0.26

シナリオ価格

B

Bear

Bear · 25%EKSO

$0.25

シナリオ価格

イベントタイムライン

2026-01-21 (ET)

08:40:00

Ekso Bionics Completes Private Placement, Raising Approximately $5.9 Million

2025-12-31 (ET)

08:10:00

H.C. Wainwright Downgrades Ekso Bionics to Neutral

2025-12-30 (ET)

16:50:00

Major US Indices Close Marginally Lower, Nasdaq Down 0.24%

12:00:00

Major U.S. Averages Mostly Unchanged Near Noon

10:40:00

Ekso Bionics Trading Halted Due to Volatility

ニュース

EKSO FAQ — answered by Alphio AI

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector (GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC industry).

EKSO is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock has short-term technical strength, but the business fundamentals are weak, there is no fresh news catalyst, no supportive options activity, and no strong institutional or insider buying signal. I would not buy this name now; the better call is to avoid it and wait for a materially stronger fundamental setup.

1 analysts cover EKSO: 1 rate it Buy, 0 Hold and 0 Sell.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める